- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-Flag magnetic beads
- Anti-Flag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly FLAG Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
Zandelisib
Synonyms: ME-401; PWT-143
Zandelisib(ME-401; PWT-143) is an orally bioavailable inhibitor of the phosphatidylinositide 3-kinase (PI3K). It selectively inhibits the delta isoform of PI3K (p110δ) and prevents the activation of the PI3K/AKT signaling pathway with an IC50 of 3.5 nM. It functions as an antineoplastic agent.
Zandelisib Chemical Structure
CAS: 1401436-95-0
Purity & Quality Control
Zandelisib Related Products
| Related Targets | p110α p110β p110δ p110γ C2β Vps34 | Click to Expand |
|---|---|---|
| Related Compound Libraries | Kinase Inhibitor Library PI3K/Akt Inhibitor Library Apoptosis Compound Library Cell Cycle compound library NF-κB Signaling Compound Library | Click to Expand |
Signaling Pathway
Choose Selective PI3K Inhibitors
Biological Activity
| Description | Zandelisib(ME-401; PWT-143) is an orally bioavailable inhibitor of the phosphatidylinositide 3-kinase (PI3K). It selectively inhibits the delta isoform of PI3K (p110δ) and prevents the activation of the PI3K/AKT signaling pathway with an IC50 of 3.5 nM. It functions as an antineoplastic agent. | ||
|---|---|---|---|
| Targets |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04533581 | Active not recruiting | Indolent B-cell Non-Hodgkin''s Lymphoma |
Kyowa Kirin Co. Ltd. |
September 17 2020 | Phase 2 |
| NCT03768505 | Terminated | Follicular Lymphoma (FL)|Non Hodgkin Lymphoma|Marginal Zone Lymphoma |
MEI Pharma Inc. |
June 25 2019 | Phase 2 |
| NCT03985189 | Active not recruiting | Relapsed or Refractory Indolent B-cell Non-Hodgkin''s Lymphoma |
Kyowa Kirin Co. Ltd. |
April 29 2019 | Phase 1 |
| NCT02914938 | Terminated | Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma (FL)|Marginal Zone B Cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|High Grade Non-Hodgkin''s Lymphoma|Mantle Cell Lymphoma (MCL) |
MEI Pharma Inc. |
October 2016 | Phase 1 |
Chemical Information & Solubility
| Molecular Weight | 576.68 | Formula | C31H38F2N8O |
| CAS No. | 1401436-95-0 | SDF | Download Zandelisib SDF |
| Storage (From the date of receipt) | |||
|
In vitro |
DMSO : 13 mg/mL ( (22.54 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.) Ethanol : 3 mg/mL Water : Insoluble |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
Preparing Stock Solutions
Molarity Calculator
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
* Indicates a Required Field
Tags: buy Zandelisib | Zandelisib supplier | purchase Zandelisib | Zandelisib cost | Zandelisib manufacturer | order Zandelisib | Zandelisib distributor
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.